161 related articles for article (PubMed ID: 18392690)
1. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
Oz O; Tuncel E; Eryilmaz S; Fazlioglu M; Gul CB; Ersoy C; Ocak N; Dirican M; Cangur S; Baran I; Imamoglu S
Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
Oz Gul O; Tuncel E; Yilmaz Y; Ulukaya E; Gul CB; Kiyici S; Oral AY; Guclu M; Ersoy C; Imamoglu S
Metabolism; 2010 Jan; 59(1):64-9. PubMed ID: 19709689
[TBL] [Abstract][Full Text] [Related]
3. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
5. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
[TBL] [Abstract][Full Text] [Related]
6. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
10. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
[TBL] [Abstract][Full Text] [Related]
11. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Chogtu B; Singh NP; Chawla S; Gupta U
Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.
Kim HJ; Kim SK; Shim WS; Lee JH; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
Diabetes Res Clin Pract; 2008 Jul; 81(1):42-9. PubMed ID: 18394743
[TBL] [Abstract][Full Text] [Related]
14. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
[TBL] [Abstract][Full Text] [Related]
15. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients.
Breslavsky A; Frand J; Matas Z; Boaz M; Barnea Z; Shargorodsky M
Clin Nutr; 2013 Dec; 32(6):970-5. PubMed ID: 23561637
[TBL] [Abstract][Full Text] [Related]
16. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
17. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
Diabetes Care; 2014 Jun; 37(6):1706-11. PubMed ID: 24705615
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study.
Shimizu H; Oh-I S; Tsuchiya T; Ohtani KI; Okada S; Mori M
Diabet Med; 2006 Mar; 23(3):253-7. PubMed ID: 16492207
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
[TBL] [Abstract][Full Text] [Related]
20. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
